Obicetrapib effects on antioxidant levels in blood, HDL, and eye tissue
Official title: A Randomized, Double-Blind, Placebo-Controlled Parallel Trial to Assess the Effects of Obicetrapib on Levels of Antioxidants in Plasma and HDL Particles in Healthy Volunteers: The VERMEER Study
Run by NewAmsterdam Pharma · NCT06982508 · Data updated 2026-11-12
This trial will test whether taking obicetrapib daily for four months helps healthy adults absorb more antioxidants into their blood, HDL particles, and retinal tissue compared with a placebo.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | NewAmsterdam Pharma Industry-sponsored |
| Locations | 1 site (Miami Gardens, Florida) |
| Status | Recruiting |
| Started | September 9, 2025 |
| Main results expected | September 2026 |
| Study ends | December 2026 |
| Registry record updated | October 20, 2025 |
| Trial ID | NCT06982508 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are healthy adults with visual acuity better than 20/60 in both eyes who do not have type 2 diabetes, active liver disease, or clinically significant macular pathology and who can attend visits in Miami Gardens, Florida.
✕Probably not a fit
People with type 2 diabetes, active liver disease, or clinically significant macular pathology are excluded and would not be expected to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Healthy adult volunteers without diabetes, active liver disease, or significant macular pathology will take either obicetrapib 10 mg or a matching placebo each day for four months. Participants will attend clinic visits every eight weeks for safety checks, blood draws, and eye examinations to measure antioxidant levels in plasma, HDL particles, and retinal tissue. The study compares antioxidant measurements between the obicetrapib and placebo groups to see if the drug changes absorption or distribution of antioxidants. The trial is sponsored by NewAmsterdam Pharma and conducted at a single site in Miami Gardens, Florida.
Why it matters
Potential benefit: If successful, obicetrapib could raise antioxidant levels in blood and eye tissues, which might help protect against oxidative damage.
How similar studies have gone: While obicetrapib and related CETP inhibitors have been studied for effects on lipids, using obicetrapib to change antioxidant absorption in plasma, HDL, or eye tissue is largely untested in humans.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Visual acuity \> 20/60 in both eyes with or without corrective lenses Exclusion Criteria: * Type 2 diabetes * Active liver disease * Any clinically significant macular pathology
Where it's running
-
Excellence Medical Research
Miami Gardens, Florida, United States Recruiting
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.